NCT00742105View on ClinicalTrials.gov

Phase I Study to Determine the Maximum Tolerate Dose (MTD) of BGT226 in Advanced Solid Tumors in Japan

PHASE1TerminatedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 17, 2008

Primary Completion Date

December 22, 2009

Study Completion Date

December 22, 2009

Conditions
CancerSolid TumorAdvanced Solid Tumor
Interventions
DRUG

BGT226

Trial Locations (2)

464-8681

Novartis Investigative Site, Nagoya

650-0017

Novartis Investigative Site, Kobe

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY